Navigation Links
Macrocyclics presenta nuevos productos
Date:1/10/2014

DALLAS, 10 de enero de 2014 /PRNewswire/ -- Macrocyclics, Inc. (compañía de AREVA Med) anunció hoy la presentación de cuatro nuevos productos que ampliarán las aplicaciones de imágenes PET con cobre-64 y galio-68 usando plataformas quelatantes basadas en NOTA. Además, un nuevo conjugado de DOTA basado en serotonina ofrece el potencial para obtener imágenes de neurotransmisión serotoninérgicas utilizando un radioisótopo o con gadolinio mediante imágenes por resonancia magnética (MRI).

(Logo: http://photos.prnewswire.com/prnh/20130523/DA20136LOGO)

Visite www.macrocyclics.com para obtener más información.

MÁS ACERCA DE MACROCYCLICS
Macrocyclics es el líder global en tecnologías de agentes quelatantes de alto desempeño para la medicina desde 1995. El equipo de Macrocyclics se dedica a proveer a los clientes agentes quelatantes y servicios tanto establecidos como innovadores para superar los desafíos de las imágenes moleculares y la medicina nuclear. www.macrocyclics.com

MÁS ACERCA DE AREVA MED
AREVA Med es una subsidiaria de AREVA que se especializa en el desarrollo de tratamientos innovadores para luchar contra el cáncer. AREVA Med creó nuevos procesos para producir plomo-212 (²¹²Pb) de alta pureza, un metal poco común que actualmente se encuentra en el centro de prometedoras investigaciones de medicina nuclear. En 2011, AREVA Med adquirió Macrocyclics, líder global en tecnología de agentes quelatantes de alto desempeño. AREVA Med también formó alianzas con socios científicos de primer nivel, como el Instituto Nacional del Cáncer (National Cancer Institute, NCI), la Universidad de Alabama en Birmingham (University of Alabama at Birmingham, UAB) y el Instituto Nacional Francés de Salud e Investigación Médica (French National Institute of Health and Medical Research, Inserm). En 2012, AREVA Med y Roche formaron una alianza estratégica para crear nuevos tratamientos avanzados de radioinmunoterapia alfa para atacar y matar ciertos tipos de células cancerígenas muy agresivas. Para obtener más información: http://arevamed.areva.com/ o www.targetedtrials.com.

Macrocyclics
Garry Kiefer
Teléfono: +1 972 250 2248
Fax: +1 972 250 2245
info@macrocyclics.com

AREVA Med
Alison Tise
Teléfono: +1 301 841 1673
Fax: +1 434 382 4250
alison.tise@areva.com

FUENTE  Macrocyclics, Inc.

FUENTE Macrocyclics, Inc.


'/>"/>
SOURCE Macrocyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Macrocyclics apresenta novos produtos
2. Macrocyclics introduces new products
3. Healthcare Companies Report Conference Presentation Schedule, Stock Price Updates, and Clinical Study Results - Research Report on Medivation, Envision Healthcare, Fonar, Idera Pharma, and Neurocrine
4. Presentation Schedules, Stock Movements, Agreements, and New Appointments - Research Report on Celgene, Merck, Bristol-Myers, Valeant, and Mylan
5. Cepheid to Webcast Upcoming Financial Presentation
6. Quarterly Dividends, Clinical Trial Results, Dental Exhibition Updates, and Upcoming Presentation Schedules - Research Report Quest Diagnostics, Avanir, Sirona, Ligand and Genomic Health
7. Pharmacyclics Announces Data Presentations for Ibrutinib in B-Cell Malignancies
8. Cell Therapeutics Announces Presentation of Interim Results from Phase 2 Tosedostat Trial in Older Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) at ASH Annual Meeting
9. Ambit Announces Presentations At The 55th Annual Meeting Of The American Society Of Hematology (ASH)
10. Highland Instruments, Inc., Announces Presentation of "Effects of Electrosonic Stimulation on the Perception of Chronic Pain Due to Osteoarthritis of the Knee."
11. Nora Therapeutics Announces New Time for Presentation at the Oppenheimer 24th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... , Feb. 4, 2016 For hospitals ... or those already participating in the program, the Health ... referred to as the , Mega-Guidance , could have ... guidance is published in September 2016. Essential ... and Service Marketing , summarizes the Mega-Guidance,s key proposed ...
(Date:2/4/2016)... -- Worldwide Radiology Oncology surgical robot markets are ... systems provide a way to improve traditional open ... systems pinpoint the delivery of radiation precisely, eliminating ... problem previously, limiting the quantity of radiation that ... far beyond what has been available, promising a ...
(Date:2/4/2016)... , Feb. 4, 2016 Wegener ... Global Markets Direct,s, ,Wegener Polyangiitis - Pipeline ... Wegener Polyangiitis,s therapeutic pipeline. This report provides ... Polyangiitis, complete with comparative analysis at various stages, ... (MoA), route of administration (RoA) and molecule type, ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... 05, 2016 , ... The Lymphoma Research Foundation (LRF) – ... serving the lymphoma community through a comprehensive series of education programs, outreach initiatives ... Tasting Event at the La Gorce Country Club in Miami Beach on March ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... Give ... allow users to search for and donate to Give To Cure’s campaign that is ... app that lets users make and share payments through a smart device. In 2015 ...
(Date:2/5/2016)... ... 2016 , ... Stuart Bentkover, MD, FACS is thrilled to announce ... most effective tattoo removal today, Dr. Bentkover is the only doctor in Central Massachusetts ... PicoSure has been approved by the Food and Drug Administration (FDA) as a safe ...
(Date:2/5/2016)... ... February 05, 2016 , ... California Mobile Kitchens ... debut of their latest mobile kitchen model, featuring customizable stainless steel interiors and ... commercial kitchens for use anywhere in the U.S. Many of their units can ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... Susan ... Medicare San Luis Obispo users can expect to see in 2016. To view the ... most significant changes will directly impact many San Luis Obispo seniors who rely on ...
Breaking Medicine News(10 mins):